StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > focusing on cancer

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Jan 15, 2021 1:01pm

146 Views

Post# 32306958

RE:RE:RE:RE:focusing on cancer

LithLover wrote: I wonder how many times people need to get tested.

Tested anytime you fly, tested anytime you or a family member is in close contact with a case, tested to attend a sporting event, tested for work, tested if you are a front line worker. Even after a vaccine, testing will continue for another 6-12 months. This is bigger than we all think.

frewil11 wrote: When you divide the total cases of COVID in the US into the US population it works out to around 1 in every 14 people have been confirmed through testing , but who knows how much cases there really has been , so we will say 1 out of ten people have had it , by the time they vaccinate everyone the whole population will have had it. JMHO

Thats it. The extended revenue stream will add a layer of financial security for this company and allow Tripp some additional marketing leverage with Aristotle. I know he does not want to sell this company, however I have to think that as this sector heats up someone will come to their senses and make a serious affiliation attempt for the technology - we are leading in the field and ready to go. As for sp, I have to believe we are on the cusp of greatness as that covid revenue shows itself with the Aristotle overlap. My biggest concern is simply getting it out in Q1 as promised.